GLP-1 drugs like Ozempic help with weight loss, but how do they stack up against bariatric surgery? A new study breaks it ...

Clinical trials show weight loss between 15% to 21% for GLP-1s, but this study suggests that weight loss in the real world is ...

Senior author and NYU Assistant Professor Dr Karan Chhabra on larger studies to address drug efficacy and who could do better ...

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...

A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...

Weight loss drugs, including Wegovy (semaglutide) and Mounjaro (tirzepatide), are becoming increasingly popular among those ...

(Reuters) -Current weight-loss methods such as lifestyle changes, surgery, and popular therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss that can ...

A trial pitting weight loss jab Mounjaro against competitor Wegovy ended with one clear winner, and Mounjaro is getting ...

A study from Mass General Brigham and Harvard Medical School raises questions about a new class of weight loss drugs — and ...

Many focus on what weight-loss drugs take away: pounds. But they also offer patients something new: a sense of agency.

Patients on GLP-1 medications lost about half as much weight as participants did in clinical trials, NYU researchers found.

Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients lose ...